Inclisiran单次或两次给药对低密度脂蛋白胆固醇水平的影响:ORION-1随机临床试验一年随访
ORION-1预设分析纳入501例最大耐受他汀治疗后LDL-C仍升高的患者,随机接受inclisiran单次(200/300/500 mg)或两次(100/200/300 mg,第1和90天)或安慰剂。单次给药1年平均LDL-C降幅29.5%–38.7%,两次给药29.9%–46.4%(组间P<.001),两次300 mg方案第360天应答比例最高且1年平均降幅最大;不良事件发生率与安慰剂相似。
要点
- inclisiran单次或两次给药可实现1年持久LDL-C降低,两次300 mg方案效果最佳。
- 两次300 mg方案第360天应答比例最高,1年平均LDL-C降幅最大。
- 不良事件发生率至1年与安慰剂相似,支持低频给药便利性。
核心结论
- inclisiran治疗可在1年内持久降低LDL-C。
- inclisiran可能提供一种低频给药降低LDL-C的新方法。
研究设计与样本
- 随机、双盲、安慰剂对照多中心2期临床试验的预设分析。
- 纳入501例最大耐受他汀治疗后LDL-C仍升高的患者。
- 每月随访LDL-C和PCSK9至LDL-C回到基线变化20%以内(最长360天)。
主要发现
- 单次给药1年平均LDL-C降幅29.5%–38.7%(组间P<.001)。
- 两次给药1年平均LDL-C降幅29.9%–46.4%(组间P<.001)。
- 因LDL-C未回到基线变化20%以内而随访至第360天的比例:单次给药48.3%–65.0%,两次给药55.9%–83.1%。
- 两次300 mg方案第360天应答比例最高且1年平均LDL-C降幅最大。
- 不良事件发生率至1年与安慰剂相似。
关键数值与推荐
- 单次剂量:第1天200、300或500 mg inclisiran钠。
- 两次剂量:第1天和第90天各100、200或300 mg inclisiran钠。
- 基线LDL-C为128 mg/dL(501例随机参与者)。
临床怎么用
- 对于最大耐受他汀治疗后LDL-C仍升高的患者,inclisiran低频给药可提供1年持久LDL-C降低。
- 两次300 mg方案在第360天应答比例和1年平均LDL-C降幅上表现最佳。
局限性
- 为2期临床试验的预设分析,样本量501例。
- 随访最长为360天,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. OBJECTIVE: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. DESIGN, SETTING, AND PARTICIPANTS: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20% of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. INTERVENTIONS: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. MAIN OUTCOMES AND MEASURES: Duration of time to return to within 20% of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. RESULTS: At baseline, among the 501 participants, 65% were men (n = 326 of 501), mean age was 63 years, 6% had familial hypercholesterolemia (n = 28 of 501), and 69% had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20% of their change from baseline ranged from 48.3% to 65.0% for those receiving a single dose and between 55.9% and 83.1% of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5% to 38.7% (P < .001 between groups) and from 29.9% to 46.4% (P < .001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. CONCLUSIONS AND RELEVANCE: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02597127.
引用
- Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 31553410. doi:10.1001/jamacardio.2019.3502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。